bioAffinity Technologies: HRT Financial tops 10% ownership
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
bioAffinity Technologies, Inc. (BIAF) reported that HRT Financial LP became a beneficial owner of more than 10% of outstanding common stock on September 22, 2026. Immediately following the transaction that resulted in that status, HRT Financial LP directly held 116,782 common shares. Its reported holdings also included 1,183 warrants, each exercisable for 1/450 of a common share, with an exercise price of $3,645 per whole share and an expiration date of June 22, 2027.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Warrant (rights to buy) F2 | -- | -- | -- |
| Holding | Common Stock F1 | -- | -- | -- |
Footnotes (2)
- F1. The reporting person became the beneficial owner of more than 10% of the outstanding Common Stock on September 22, 2026. The amount reported represents shares of Common Stock directly held by the reporting person immediately following the transaction that resulted in such status.
- F2. Represents 1,183 warrants held at the time described in footnote (1). Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. The underlying amount is rounded to four decimal places.
Key Figures
Key Terms
beneficial owner regulatory
warrants financial
exercise price financial
reverse stock splits technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What warrant terms did HRT Financial LP report for BIAF?
AI-generated analysis. How Rhea-AI works. Not financial advice.